In this episode, we’re bringing you highlights from a virtual salon focused on one of the biggest challenges for biotech companies, telling your story in a way that attracts funders and partners. You’ll hear advice straight from investors, communication experts, and pharma BD leaders on what resonates and why.

This hour-long conversation also introduces BioFuture 2025 Spotlight Panels, a new format designed to maximize exposure for participating companies, elevate visibility, and spark meaningful dialogue through expertly moderated discussions with real-time audience interaction. Instead of the traditional pitch presentation, Spotlight Panels create richer, more memorable experiences for audiences eager to discover and connect with the next wave of transformative biotech companies and technologies.

Join us October 13–15 in New York City for BioFuture, where therapeutic innovators, policymakers, and investors come together to assess and shape the future of healthcare. This year’s program will feature candid, unfiltered discussions on the convergence of rapidly evolving fields, including biopharma, digital medicine, big data, TechBio, AI, and more, as well as the impact of regulatory changes on the healthcare ecosystem. Register and learn more at BioFuture.com.

Moderator:
Dennis Purcell, Founder, Aisling Capital

Two industry titans explore the metamorphosis that is unfolding in health care, driven by innovation and demanded by consumers, that will profoundly transform this space as we know it.

Up to 85% of the human proteome is considered “undruggable,” with proteins that lack the pockets where traditional therapeutics can bind. But that barrier is beginning to shift.

A new wave of biotech companies is bringing forward breakthrough technologies designed to target the most elusive proteins—opening the door to therapies once thought impossible. In this episode, we explore the science, innovation, and opportunities behind cracking the code of the so-called “undruggable” proteome.

Alzheimer’s disease is a relentless and fatal illness, creating a profound health crisis for patients, families, and societies worldwide. Without meaningful progress, the societal costs will be staggering.

Global thought leaders have set an ambitious goal: to develop a treatment that can slow the progression of Alzheimer’s by 2025. While late-stage clinical successes have been elusive over the past decade, scientific understanding of the disease has advanced dramatically, particularly in the areas of early diagnosis and disease progression. This episode explores the evolving science of Alzheimer’s, the surge in drug development targeting patients in the earliest stages, and the promise that earlier intervention could deliver better outcomes for patients.

In this episode, we sit down with Amy Abernethy, Principal Deputy Commissioner of the U.S. Food & Drug Administration, for a candid conversation on disruption in healthcare.

We’ll explore how COVID has accelerated change across the system, and whether that disruption is ultimately driving positive transformation for patients, providers, and innovators.

Electricity has long been used as a therapeutic tool to restore heart rhythms, stimulate nerves and neurochemicals, and even support cellular regeneration. Today, innovation in this field is accelerating, with new medical devices and bioelectrical treatments emerging for conditions ranging from CNS diseases to cancer and diabetes.

In this episode, a panel of experts explores the latest research, the favorable regulatory environment, and the innovative business models fueling this electrifying wave of potential in bioelectrical therapeutics.

Fundraising has long been a challenge for European biopharma companies, particularly those moving programs into the clinic, due to the limitations of European public markets. But change may be on the horizon.

With the rise of virtual fundraising, European innovators are finding new opportunities to access ex-EU public and private capital. But is this trend sustainable? Where does non-dilutive funding fit? Is a NASDAQ listing the right path? And what other tools should CEOs and their teams be considering as they advance their assets? In this episode, industry leaders unpack these critical questions and explore the evolving landscape of European biopharma fundraising.